NCT00056134View on ClinicalTrials.gov

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

October 31, 2002

Primary Completion Date

October 31, 2011

Study Completion Date

May 31, 2012

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

Dendritic cell vaccine plus denileukin difitox

Trial Locations (1)

D-91052

Dermatologische Klinik mit Poliklinik - Universitaetsklinikum Erlangen, Erlangen

All Listed Sponsors
lead

University Hospital Erlangen

OTHER

NCT00056134 - Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma | Biotech Hunter | Biotech Hunter